Market Overview - The Hong Kong stock market showed a narrow fluctuation, with the Hang Seng Index down 0.18% at 24,727.78 points, the Hang Seng Tech Index down 0.12% at 5,446.61 points, and the National Enterprises Index down 0.01% at 8,882.04 points [1] - Major tech stocks mostly turned positive, with Meituan and Alibaba rising by 2.5%, Baidu by 2%, and JD.com by over 1% [1] - International spot gold returned above $3,290, leading to active performance in gold stocks [1] - The paper industry in Guangdong issued its first anti-involution initiative, resulting in a price surge in the sector, with Morning Paper and Nine Dragons Paper leading the gains [1] Company News - Daxin City Real Estate proposed a privatization plan, offering HKD 0.62 per share, a 67.57% premium over the closing price on July 17, with a total amount of approximately HKD 29.32 billion [2] - Evergrande Auto announced a further delay in issuing a circular, now expected on August 29, 2025, involving significant related transactions [2] - Lee's Pharmaceutical received approval for Socazolimab for first-line treatment of extensive-stage small cell lung cancer in mainland China [3] - Hengrui Medicine received approval for clinical trials of SHR-8068 injection, Abediteran injection, and Bevacizumab injection [4] - Hengrui Medicine also received approval to conduct clinical trials for HRS-5041, intended for prostate cancer treatment [5] - Shenzhen Expressway reported a revenue of RMB 106 million from the outer ring project in June [6] - Automotive Home reported a total revenue of RMB 3.212 billion for the first half of the year, a decrease of 7.75% year-on-year, with net profit down 15.99% to RMB 772 million [8] - China Petroleum and Chemical Corporation expects a mid-term net profit of RMB 20.1 billion to RMB 21.6 billion, a year-on-year decline of 39.5% to 43.7% [9] Institutional Insights - Dongwu Securities expressed concerns about rising overseas risks, including the potential impact of increasing dollar assets on global funds' attention to Chinese assets [10] - CITIC Securities noted an increasing confidence trend in certain sub-sectors, with earnings expectations being revised upward ahead of earnings reports, particularly in new energy vehicles, semiconductors, and consumer electronics [10][11] - Ping An Securities highlighted the low valuation of the Hong Kong market and the increasing trading activity under the "profit-making effect," maintaining a positive long-term outlook [11] - Huatai Securities remains optimistic about opportunities in the Hong Kong market, suggesting that the Hang Seng Tech Index has significant recovery potential [11]

A股机器人、减速器概念局部异动，中马传动直线拉升涨停，夏厦精密触及涨停，东杰智能涨超15%， 荣泰健康、兰剑智能、优德精密、德马科技等跟涨。 ...

Group 1 - Overseas business development continues to exceed expectations, with CSPC Pharmaceutical Group licensing its oral GLP-1 small molecule to Madrigal for a record upfront payment of $120 million, highlighting the premium capability of Chinese technology platforms [1] - Breakthrough in treatment paradigms with Shuyou Shen's C5a antibody BDB-001, which outperformed hormone therapy in treating anti-neutrophil cytoplasmic antibody vasculitis, achieving a complete response rate that is ten times higher, laying the foundation for subcutaneous formulations to enter international markets [1] - The National Healthcare Security Administration supports high-level innovative drugs, indicating satisfaction with pricing levels that correspond to high investment and risk, and is implementing measures to expedite the clinical launch of new drugs [1] Group 2 - Huazhong Securities emphasizes that innovative hard technology will remain a key focus in the pharmaceutical sector, including innovative drugs, devices, AI healthcare, and emerging technologies like brain-computer interfaces and robotics [2] - The Hong Kong Medical ETF closely tracks the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index, which selects 50 liquid and large-cap healthcare companies to reflect the overall performance of the sector [2] Group 3 - As of July 31, 2025, the top ten weighted stocks in the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index account for 62.91% of the index, including companies like Innovent Biologics, WuXi Biologics, and CSPC Pharmaceutical Group [3]

Core Viewpoint - Jiangnan Yifan's stock price closed at 41.35 yuan on July 31, 2025, reflecting a decrease of 1.23 yuan or 2.89% from the previous trading day [1] Group 1: Company Overview - Jiangnan Yifan specializes in the research, development, production, and sales of motors and transmission equipment, with applications in industrial automation and robotics [1] - The company's segments include motors, humanoid robots, and robotic actuators [1] Group 2: Recent Developments - On the evening of July 31, Jiangnan Yifan announced that its director and general manager, Liu Songyan, plans to increase his stake in the company by purchasing between 50,000 and 100,000 shares using personal funds from August 1, 2025, to January 31, 2026 [1] - On the same day, the net outflow of main funds was 12.2767 million yuan, accounting for 0.71% of the circulating market value [1]

一、对外投资概述 为贯彻新能源发展战略，进一步加快新能源产业发展，提升重庆新铝时 代科技股份有限公司（以下简称"公司"）核心竞争力。公司拟与重庆綦江 高新技术产业开发区管理委员会签署《重庆綦江新铝时代铝合金循环利用项 目招商引资协议》（以下简称"本协议"），拟通过其全资子公司对重庆綦 江新铝时代铝合金循环利用项目总投资5亿元人民币（最终投资总额以实际投 资金额为准）。公司拟在重庆市綦江高新区北渡组团原汇程二期地块设立的 全资子公司重庆新铝时代循环科技有限公司（暂定名，最终以工商行政管理 部门核准登记为准）为本次项目的投资主体。 公司于2025年7月31日召开第二届董事会第二十二次会议，审议通过了《 关于设立全资子公司暨建设重庆綦江新铝时代铝合金循环利用项目的议案》， 董事会同意通过在重庆市綦江高新区北渡组团原汇程二期地块设立的全资子 公司重庆新铝时代循环科技有限公司建设重庆綦江新铝时代铝合金循环利用 项目，并提请股东会授权公司董事长或其授权的相关人员负责办理本次对外 投资的具体事宜（包括但不限于重庆綦江新铝时代铝合金循环利用项目相关 设立登记事宜），授权有效期自股东会审议通过之日起至本次对外投资项目 结束之日 ...

中证报中证网讯(记者王雪青)7月31日晚间，长盛基金社保业务管理部基金经理杨秋鹏在"中证点金 汇"直播间表示，下半年继续看好人工智能板块，人工智能产业整体快速向前发展的趋势不变。不过， 需要关注市场的预期与实际产业进展的差异，进而评估市场风险和个股风险。 他同时提示，人工智能等科技板块的投资还是需要保持警惕。今年以来，因为流动性充裕，市场对于个 股估值的容忍度显著提升，光模块、PCB、国产算力中业绩增长最快或者预期增长最快的公司所对应的 估值都可以作为细分领域估值的锚。未来，如果这些公司的估值回调，可能会对整个板块造成较大的调 整压力。 杨秋鹏表示，下半年将重点关注机器人和Robotaxi的商业化进程。在机器人方向，密切跟踪细分领域的 技术路线变化，同时关注国内有场景和细分领域算法优势的公司。在Robotaxi方向，海外的商业化节奏 在加快，融合了Grok模型的特斯拉智驾产品能力进一步提升。国内L3级别自动驾驶加速落地，L2.5以 上高阶智驾渗透率超过20%，城区领航渗透率在10%-15%，车企的智驾算法逐渐成熟。整体来看，产业 的技术进展和推进力度一直在加速。 ...

Core Viewpoint - Jikai Co., Ltd. has faced significant challenges over its 13 years since listing, with a market value decline of 61.19% from its peak, reflecting issues in performance and market confidence [2][7]. Group 1: Business Performance - The transportation machinery segment is the main revenue driver, accounting for 59.17% of total revenue in the first half of 2024, down from 68.91% in 2020 [3]. - Despite having a strong product line, including key equipment like 3D-formed cast scrapers, the transportation machinery business has shown signs of revenue decline, with a year-on-year decrease of 11.24% in the first three quarters of 2024 [3]. - The company has developed innovative products like explosion-proof diesel intelligent handling robots, but these have limited short-term impact on revenue [3]. Group 2: Financial Challenges - Jikai Co., Ltd. has consistently reported losses, with a net profit of -0.16 billion in 2020, narrowing to -0.02 billion in 2024, and a loss of 16.39 million in the first quarter of 2025 [5]. - There is a mismatch between R&D investment and output efficiency, with management expenses increasing by 23% year-on-year in 2024, leading to a lower return on investment compared to industry averages [5]. Group 3: Market Position and Strategic Issues - The company's market value peaked at 7.236 billion in 2017, coinciding with a boom in the coal industry, but it has struggled to find new growth avenues as the industry cycle shifted [7]. - Jikai Co., Ltd. faces increasing competition from leading firms like XCMG and SANY in the intelligent mining sector, despite benefiting from regional policy support [7]. - The company has expanded its export business to markets like Australia and Russia, but overseas revenue remains below 15%, and it lacks sufficient international certifications to enhance competitiveness [7].

1. Report Industry Investment Rating No information provided regarding the industry investment rating in the report. 2. Core Viewpoints of the Report - In July, the equity market rose significantly, but convertible bonds underperformed underlying stocks. The CSI Convertible Bond Index rose 3.83% from July 1 - 30, while the CSI All - Share Index rose 5.8%. Year - to - date, the CSI Convertible Bond Index and the CSI All - Share Index increased by 11.11% and 10.33% respectively [4]. - The healthcare sector was strong, and convertible bonds followed the upward trend but still underperformed underlying stocks. The healthcare and information technology convertible bond indices had the best performance in July, with increases of 7.82% and 7.13% respectively. The financial convertible bond index only rose 0.47% this month, while the underlying stocks rose 3.69% [5]. - Due to the significant rise of underlying stocks, the double - low strategy significantly underperformed the high - price and low - premium strategy in July. The double - low strategy index only rose 2.36% in July and 9.12% year - to - date, while the high - price and low - premium strategy rose 7.29% in July and 13.75% year - to - date [41]. 3. Summary by Relevant Catalogs 3.1 Convertible Bond Monthly Market Tracking - **Overall Market Performance**: In July, the convertible bond market underperformed underlying stocks. The CSI Convertible Bond Index rose 3.83%, and the CSI All - Share Index rose 5.8%. The convertible bond market lagged behind the CSI 500 Index by 2.92 percentage points [4]. - **By Price Classification**: In July, the Wande high - price convertible bond index rose 5.84%, significantly outperforming the low - price (+4.27%) and medium - price (+2.72%) indices. Year - to - date, the low - price (+11.78%) and high - price (+11.76%) convertible bonds had similar cumulative increases, both higher than the medium - price convertible bonds (+9.07%) [4]. - **By Convertible Bond Stock Volume**: In July, the Wande small - cap (+4.47%) and mid - cap (+4.02%) convertible bond indices were strong, outperforming the large - cap convertible bond index (+3.11%). Year - to - date, the small - cap index (+15.97%) led the large - cap (+9.02%) and mid - cap (+9.81%) indices [23]. - **By Credit Rating**: In July, the AA+ (+5.13%) and AA (+5.44%) convertible bond indices had relatively large increases. The AA - and below convertible bond index rose 4.54%, while the AAA high - rating convertible bonds still underperformed. Year - to - date, low - rating convertible bonds significantly outperformed high - rating ones, with the AA - and below convertible bonds rising 17.53%, and AA and AA+ rising 11.62% and 10.36% respectively [26]. - **By Industry**: In July, the healthcare and information technology convertible bond indices performed best, with increases of 7.82% and 7.13% respectively. The financial convertible bond index only rose 0.47%, while the underlying stocks rose 3.69%. The performance of the public utilities convertible bond index was also better than that of the underlying stocks [5]. 3.2 Convertible Bond Monthly Investment Recommendations 3.2.1 Strategy Recommendation: The Double - Low Strategy Should Focus on the Valuation Elasticity of Underlying Stocks - **July Double - Low Portfolio Performance**: The double - low portfolio constructed in July consisted of 22 bonds ranked in the bottom 5% by the double - low value. From July 1 - 30, the portfolio's return was 1.78% (equal - weighted allocation, without active screening), underperforming the CSI Convertible Bond Index by 2 percentage points [44]. - **August Double - Low Portfolio Recommendation**: After screening out bonds with high delisting/redemption risks and weak underlying stock performance and valuation expectations, 15 bonds were selected. The industries with the most bonds were light manufacturing (3), machinery and equipment (2), and non - ferrous metals (2). The average convertible bond price, conversion value, and conversion premium rate of the portfolio were 124 yuan, 117 yuan, and 7% respectively [6][48]. 3.2.2 Allocation Recommendation: Focus on the More Growth - Oriented AI and Robotics Sectors As the market risk appetite has significantly recovered, high - price and low - premium convertible bonds can be used to replace underlying stocks to better capture the upside potential of underlying stocks. It is recommended to focus on the technology sector, especially AI and robotics, which have both thematic concepts and rapid performance growth [52].

Market Performance - The CSI Cloud Computing and Big Data Theme Index increased by 1.2% [1] - The CSI Artificial Intelligence Theme Index rose by 0.5% [1] - The National Robot Industry Index decreased by 0.3% [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 1.2% [1] - The CSI New Energy Index dropped by 3.1% [1] Company Developments - Alibaba Health launched an AI medical assistant named "Hydrogen Atom," which integrates millions of core medical journal articles and supports authoritative guideline access, semantic search, AI summarization, full-text translation, and intelligent Q&A [1] - The AI assistant is designed to help clinical medical workers and researchers quickly find necessary information, enhancing medical learning and research efficiency [1] Index Overview - The Artificial Intelligence ETF tracks the CSI Artificial Intelligence Theme Index, which comprehensively covers the AI industry chain, including upstream infrastructure, midstream models, and downstream applications [2] - The Robot ETF tracks the National Robot Industry Index, which covers the entire robot industry chain, with humanoid robots making up 53% of the index [2] - The Cloud Computing ETF tracks the CSI Cloud Computing and Big Data Theme Index, focusing on the cloud computing industry and related services [3] - The Innovative Drug ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which includes stocks involved in innovative drug research, development, and production [3] - The New Energy ETF tracks the CSI New Energy Index, covering the new energy industry chain, including lithium batteries, photovoltaics, wind power, hydropower, and nuclear power [3]

金融界消息 截至2025年7月31日收盘，机器人（300024）报收于16.89元，下跌1.17%，换手率2.04%， 成交量31.28万手，成交金额5.35亿元。 资金流向方面，今日主力资金净流出3893.24万元，占比成交额7.28%。其中，超大单净流出1247.12万 元、占成交额2.33%，大单净流出2646.12万元、占成交额4.95%，中单净流出流入1346.69万元、占成交 额2.52%，小单净流入2546.55万元、占成交额4.76%。 来源：金融界 天眼查商业履历信息显示，沈阳新松机器人自动化股份有限公司，成立于2000年，位于沈阳市，是一家 以从事研究和试验发展为主的企业。企业注册资本156561.995万人民币，实缴资本9050万人民币。公司 法定代表人为张进。 通过天眼查大数据分析，沈阳新松机器人自动化股份有限公司共对外投资了29家企业，参与招投标项目 1932次，知识产权方面有商标信息91条，专利信息1875条，此外企业还拥有行政许可60个。 机器人最新一期业绩显示，截至2025一季报，公司营业总收入6.88亿元、同比减少6.14%，归属净利润 5026.64万元，同比减少24.51 ...